( aseline International Prostate Symptom ...)AEterna Zentaris' Partner, Spectrum, Discloses Detailed Phase 2,Data for Ozarelix, in BPH at Annual AUA Meeting,Health

    - Placebo;

    - Ozarelix 5 mg on Day 1 + 5 mg on Day 15;

    - Ozarelix 10 mg on Day 1 +10 mg on Day 15;

    - Ozarelix 15 mg on Day 1 + 15 mg on Day 15; or

    - Ozarelix 20 mg on Day 1 only.

Patients were followed for 28 weeks. The primary efficacy endpoint was change in IPSS at week 12 compared to baseline. Secondary efficacy endpoints included changes in IPSS, Quality of Life (QoL), patients with >= 30% and >= 40% improvement in IPSS, uroflow values (Qmax), postvoid residual (PVR) urine volume and prostate volume. Safety analysis included changes in sexual function (IIEF-5), treatment of emergent adverse events (AEs), lab values (including testosterone (T), PSA) and vital signs. Mean age was 69.1 (range 52 - 85), IPSS 19.8, Qmax 9.7 mL/sec. and prostate size (cm(3)) 41.6 at baseline.

Results

The effects developed rapidly, with noticeable activity at four weeks from starting treatment, were maximal at 12-16 weeks, and persisted for the 6 month observation period. At week 12, all ozarelix-treated groups showed improvement with the greatest improvement in the 15 mg + 15 mg group. Change from baseline in IPSS was 8.6 (p<0.001); change from baseline in urine flow was 4.7 (p=0.002); T levels declined transiently and returned to baseline in most patients by 4 weeks and all patients by 6 weeks following dosing. Based on IIEF, there was no effect seen on erectile function.

Serious adverse events were reported in 4 patients on ozarelix (myocardial infarction, pneumonitis, hypotension, renal colic), but were not considered treatment related. No systemic allergic reactions were seen and the injections were well tolerated.

    Conclusions


    - Ozarelix was well tolerated;

    - Statistically sig
'"/>




Page: 1 2 3 4 5 
Related medicine technology :

1. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results
for Anti-Cancer Compound Perifosine at ASCO Meeting
2. AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist
JMR-132 at the AACR Annual Meeting in Los Angeles
3. AEterna Zentaris Discloses First In Vitro Data for its PI3K
Inhibitors at the AACR Annual Meeting in Los Angeles
4. AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors
and In Vivo Results for a GHRH Antagonist at the AACR Annual
Meeting in Los Angeles
5. AEterna Zentaris Reports Positive Results with Cetrorelix in BPH
for Japanese Phase 2a Trial
6. terna Zentaris Discloses First In Vitro Data for its PI3K

Inhibitors at the AACR Annual Meeting in Los Angeles
7. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year
Alemtuzumab in Multiple Sclerosis Data Presented at AAN
8. Data Available From Erbitux Phase III Study in First-Line Treatment
of Advanced Lung Cancer
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral
Anticoagulant, Presented Today at the XXIst Congress of the
International Society on Thrombosis and Haemostasis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in
Randomized Phase IIB Aerolef Trial
11. Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis